Susceptometric avaliation of chelation with deferoxamine
نویسندگان
چکیده
منابع مشابه
Indolent zygomycosis associated with deferoxamine chelation therapy.
This paper describes a 71-year-old man with myelodysplasia who required multiple transfusions and subsequent deferoxamine chelation therapy and who then developed indolent cutaneous and probable pulmonary infection with Rhizopus species. The patient did not have rapidly progressive infection as has been described in almost all previously reported deferoxamine-treated patients with zygomycosis. ...
متن کاملCombined chelation therapy with deferasirox and deferoxamine in thalassemia.
Iron overload is the primary cause of mortality and morbidity in thalassemia major despite advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and efficacy of combined therapy with deferasirox (DFX, 20-30 mg/kg daily) and deferoxamine (DFO, 35-50mg/kg on 3-7 days/week) in 22 patients with persistent iron overload or organ damage. In the 18 subjects completi...
متن کاملIron chelation adherence to deferoxamine and deferasirox in thalassemia.
The Thalassemia Clinical Research Network collected adherence information from 79 patients on deferoxamine and 186 on deferasirox from 2007 to 2009. Chelation adherence was defined as percent of doses administered in the last 4 weeks (patient report) out of those prescribed(chart review). Chelation history since 2002 was available for 97 patients currently on deferoxamine and 217 on deferasirox...
متن کاملChelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
A 65-year-old female with biopsy-confirmed nephrogenic systemic fibrosis (NSF) received a kidney transplantation. Despite good kidney function, her symptoms continued to progress. Deferoxamine was administered intramuscularly at 500 mg/day and later 1000 mg/day after 1 week with no adverse effects. Urine excretion of gadolinium increased from 6.0 μg/day to 11.6 μg/day and subsequently to 13.0 μ...
متن کاملMyocardial iron loading in patients with thalassemia major on deferoxamine chelation.
BACKGROUND Heart failure secondary to myocardial iron loading remains the leading cause of death in thalassemia major (TM). We used cardiovascular magnetic resonance (CMR) to assess the prevalence of myocardial iron overload and ventricular dysfunction in a large cohort of TM patients maintained on conventional chelation treatment with deferoxamine. METHODS A mobile CMR scanner was transporte...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Revista Brasileira de Hematologia e Hemoterapia
سال: 2008
ISSN: 1516-8484
DOI: 10.1590/s1516-84842008000400019